Given that SHP is an important target gene of FXR in the liver and that SHP is strongly associated with lipid metabolism, it was hypothesized that the FXR-induced up-regulation of SHP participated in the pharmacological effect of Gyps on HFD-induced NASH in mice. This evidence concerns the gene NR0B2 and metabolic dysfunction-associated steatohepatitis.